UK markets closed

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
1.4550-0.0550 (-3.64%)
As of 12:05PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.5100
Open1.5500
Bid1.4700 x 800
Ask1.4800 x 900
Day's range1.4550 - 1.5500
52-week range1.4550 - 3.1300
Volume258,961
Avg. volume1,285,746
Market cap245.252M
Beta (5Y monthly)1.71
PE ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings date09 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.40
  • Business Wire

    Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022

    CARLSBAD, Calif., January 24, 2022--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the B. Riley Securities 2022 Virtual Oncology Conference, in a fireside chat hosted by Mayank Mamtani, Managing Director, Senior Biotech Research Analyst and Group Head of Healthcare Research at B. Riley Securi

  • Business Wire

    Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

    CARLSBAD, Calif., January 04, 2022--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference. The corporate presentation will be available to investors on demand, starting on January 10, 2022 at 7:00am ET on the Events and Presentations section of Lineage’s websi

  • Motley Fool

    Why Lineage Cell Therapeutics Zoomed Higher Today

    The biotech stands to reap hundreds of millions of dollars from a new collaboration with a top pharmaceutical player.